BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 33165713.
- Also identified by DOI 10.1007/s00256-020-03665-9.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
BRAF and MEK inhibitor combination therapy is the standard treatment for patients with BRAF V600E mutant metastatic melanoma. Neutrophilic panniculitis is a known rare complication of BRAF inhibitor therapy and can act as a potential mimic of melanoma metastases on <sup>18</sup>F-FDG PET/CT. In this case series, we present three cases of BRAF inhibitor-induced panniculitis in patients being treated for BRAF-mutant metastatic melanoma and emphasize the use of ultrasound to differentiate between panniculitis lesions, which are typically ill-defined echogenic masses and subcutaneous soft tissue melanoma metastases, which present as hypoechoic vascular masses.
Medical subject headings
- Melanoma
- Panniculitis
- Skin Neoplasms